Boston Scientific Co. (NYSE:BSX) Shares Purchased by Waldron Private Wealth LLC

Waldron Private Wealth LLC lifted its stake in Boston Scientific Co. (NYSE:BSX) by 3.1% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 5,098 shares of the medical equipment provider’s stock after purchasing an additional 152 shares during the quarter. Waldron Private Wealth LLC’s holdings in Boston Scientific were worth $427,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in BSX. Park Avenue Securities LLC lifted its holdings in Boston Scientific by 12.8% during the 1st quarter. Park Avenue Securities LLC now owns 12,435 shares of the medical equipment provider’s stock worth $852,000 after buying an additional 1,413 shares in the last quarter. Brookstone Capital Management lifted its holdings in Boston Scientific by 35.0% during the 1st quarter. Brookstone Capital Management now owns 14,300 shares of the medical equipment provider’s stock worth $979,000 after buying an additional 3,710 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Boston Scientific by 10.9% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 66,024 shares of the medical equipment provider’s stock worth $4,522,000 after buying an additional 6,485 shares in the last quarter. Tlwm acquired a new stake in Boston Scientific during the 1st quarter worth approximately $927,000. Finally, 180 Wealth Advisors LLC lifted its holdings in Boston Scientific by 36.5% during the 1st quarter. 180 Wealth Advisors LLC now owns 5,621 shares of the medical equipment provider’s stock worth $385,000 after buying an additional 1,504 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Down 0.0 %

BSX stock opened at $88.02 on Wednesday. Boston Scientific Co. has a one year low of $49.15 and a one year high of $88.79. The stock has a market capitalization of $129.13 billion, a PE ratio of 73.97, a price-to-earnings-growth ratio of 2.87 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. The company has a fifty day moving average of $82.97 and a 200-day moving average of $77.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, topping the consensus estimate of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The company had revenue of $4.12 billion during the quarter, compared to analysts’ expectations of $4.02 billion. During the same quarter last year, the business earned $0.53 EPS. The business’s revenue was up 14.5% on a year-over-year basis. As a group, analysts expect that Boston Scientific Co. will post 2.4 EPS for the current year.

Insider Transactions at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $85.00, for a total value of $11,264,795.00. Following the completion of the sale, the executive vice president now owns 160,467 shares in the company, valued at $13,639,695. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $74.12, for a total value of $517,579.96. Following the completion of the sale, the executive vice president now owns 40,188 shares in the company, valued at $2,978,734.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the completion of the sale, the executive vice president now owns 160,467 shares of the company’s stock, valued at $13,639,695. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 316,253 shares of company stock worth $26,714,298. Company insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on BSX. BTIG Research increased their price objective on shares of Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Stifel Nicolaus increased their price objective on shares of Boston Scientific from $85.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Morgan Stanley increased their price objective on shares of Boston Scientific from $79.00 to $92.00 and gave the company an “overweight” rating in a research report on Monday, July 15th. Canaccord Genuity Group increased their price objective on shares of Boston Scientific from $88.00 to $98.00 and gave the company a “buy” rating in a research report on Monday. Finally, Robert W. Baird increased their price objective on shares of Boston Scientific from $90.00 to $91.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average price target of $90.68.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.